Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 10.8 %

NASDAQ CARA opened at $0.35 on Tuesday. The firm has a market capitalization of $18.92 million, a P/E ratio of -0.17 and a beta of 0.68. The company has a 50-day moving average price of $0.29 and a 200-day moving average price of $0.42. Cara Therapeutics has a 52 week low of $0.24 and a 52 week high of $1.31.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The business had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. As a group, equities research analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Trading of Cara Therapeutics

A hedge fund recently raised its stake in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN lifted its stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,935,718 shares of the biopharmaceutical company’s stock after acquiring an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned approximately 3.54% of Cara Therapeutics worth $499,000 at the end of the most recent reporting period. 44.66% of the stock is owned by hedge funds and other institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.